Jan Vilsvik

1.1k total citations
22 papers, 827 citations indexed

About

Jan Vilsvik is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Jan Vilsvik has authored 22 papers receiving a total of 827 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 8 papers in Physiology. Recurrent topics in Jan Vilsvik's work include Asthma and respiratory diseases (8 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Research Studies (7 papers). Jan Vilsvik is often cited by papers focused on Asthma and respiratory diseases (8 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Research Studies (7 papers). Jan Vilsvik collaborates with scholars based in Norway, Sweden and United Kingdom. Jan Vilsvik's co-authors include Stein Sundstrøm, Ulf Aasebø, Roy M. Bremnes, Nils P. Boye, Stein Kaasa, Einar Hannisdal, T Vigander, Steinar Aamdal, Ragnar Dahle and Reidulv Hatlevoll and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Clinical Chemistry.

In The Last Decade

Jan Vilsvik

22 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Vilsvik Norway 11 584 414 375 236 126 22 827
Der Sheng Sun South Korea 15 226 0.4× 46 0.1× 120 0.3× 228 1.0× 62 0.5× 40 570
Akiko Fujii Japan 12 152 0.3× 49 0.1× 215 0.6× 158 0.7× 31 0.2× 52 459
Hisashi Mitsufuji Japan 14 313 0.5× 72 0.2× 306 0.8× 74 0.3× 75 0.6× 46 499
Sumio Matsumoto Japan 11 219 0.4× 45 0.1× 140 0.4× 90 0.4× 37 0.3× 31 475
Minehiko Inomata Japan 14 212 0.4× 67 0.2× 170 0.5× 84 0.4× 91 0.7× 54 457
Lawrence M. Knab United States 16 309 0.5× 46 0.1× 269 0.7× 238 1.0× 18 0.1× 31 791
Toshiro Miwa Japan 11 163 0.3× 57 0.1× 123 0.3× 64 0.3× 67 0.5× 43 362
Marianne Corbel France 7 66 0.1× 30 0.1× 218 0.6× 103 0.4× 75 0.6× 8 380
Grant N. Stemmerman United States 8 338 0.6× 82 0.2× 151 0.4× 89 0.4× 28 0.2× 12 633
Dong‐Hao Wu China 13 259 0.4× 192 0.5× 87 0.2× 116 0.5× 5 0.0× 35 548

Countries citing papers authored by Jan Vilsvik

Since Specialization
Citations

This map shows the geographic impact of Jan Vilsvik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Vilsvik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Vilsvik more than expected).

Fields of papers citing papers by Jan Vilsvik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Vilsvik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Vilsvik. The network helps show where Jan Vilsvik may publish in the future.

Co-authorship network of co-authors of Jan Vilsvik

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Vilsvik. A scholar is included among the top collaborators of Jan Vilsvik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Vilsvik. Jan Vilsvik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2008). Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology. 26(26). 4261–4267. 124 indexed citations
2.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2007). A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study. Journal of Clinical Oncology. 25(18_suppl). 7523–7523. 8 indexed citations
3.
4.
Plessen, Christian von, Bengt Bergman, R. M. Bremnes, et al.. (2006). Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. British Journal of Cancer. 95(8). 966–973. 124 indexed citations
5.
Bergman, Bengt, Sverre Sörenson, Richard Stephens, et al.. (2003). O-57 Quality of life as related to duration of chemotherapy in advanced non-small cell lung cancer: A randomized study comprising 297 patients. Lung Cancer. 41. S19–S20. 2 indexed citations
6.
Vilsvik, Jan, Jaro Ankerst, Mona Palmqvist, et al.. (2001). Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis®. Respiratory Medicine. 95(6). 484–490. 28 indexed citations
7.
Bremnes, Roy M., et al.. (2001). Multicenter Phase II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 19(15). 3532–3538. 28 indexed citations
8.
Bremnes, Roy M., Stein Sundstrøm, Jan Vilsvik, & Ulf Aasebø. (1999). Paclitaxel in combination with cisplatin, etoposide and thoracic radiotherapy for limited small cell lung cancer. A Phase II study. European Journal of Cancer. 35. S253–S254. 2 indexed citations
9.
Bremnes, Roy M., Stein Sundstrøm, Ulf Aasebø, & Jan Vilsvik. (1997). 206 Treatment of limited small cell lung cancer (SCLC) with paclitaxel, cisplatin, etoposide and radiation therapy. Lung Cancer. 18. 54–54. 4 indexed citations
10.
Vilsvik, Jan, et al.. (1996). Efficacy and Duration of Salmeterol Powder Inhalation in Protecting Against Exercise-Induced Bronchoconstriction. Annals of Allergy Asthma & Immunology. 76(1). 57–60. 22 indexed citations
11.
Walstad, R. A., et al.. (1995). The Pharmacokinetics and Distribution of Ofloxacin into the Lower Respiratory Tract. Drugs. 49(Supplement 2). 344–345. 1 indexed citations
12.
Vilsvik, Jan, et al.. (1991). Comparison between Bricanyl Turbuhaler and Ventolin metered dose inhaler in the treatment of exercise-induced asthma in adults.. PubMed. 67(3). 315–8. 16 indexed citations
13.
Romslo, Inge, et al.. (1988). Theophylline determined by a bedside immunochromatographic method.. Clinical Chemistry. 34(2). 428–428. 1 indexed citations
14.
Vilsvik, Jan, et al.. (1988). A comparative study of the effect of three doses of nedocromil sodium and placebo given by pressurized aerosol to asthmatics with exercise-induced bronchoconstriction.. PubMed. 61(5). 367–70. 12 indexed citations
15.
Vilsvik, Jan, et al.. (1983). Stabilization of a diluted aqueous mite allergen preparation by addition of human serum albumin. Clinical & Experimental Allergy. 13(2). 149–153. 14 indexed citations
16.
Vilsvik, Jan, et al.. (1976). Effect of atenolol on ventilatory and cardiac function in asthma.. BMJ. 2(6033). 453–455. 35 indexed citations
17.
Vilsvik, Jan, et al.. (1976). The effect of a new anti‐allergic drug ICI 74, 9I7, given by aerosol, on nasal stenosis induced by allergen. Clinical & Experimental Allergy. 6(5). 487–491. 4 indexed citations
18.
Vilsvik, Jan, et al.. (1976). Beta1‐blocker (Practolol) and Exercise in Patients with Chronic Obstructive Lung Disease. Acta Medica Scandinavica. 199(1-6). 61–64. 6 indexed citations
19.
Vilsvik, Jan, et al.. (1975). The effect of beclomethasone dipropionate aerosol on allergen induced nasal stenosis. Clinical & Experimental Allergy. 5(3). 291–294. 37 indexed citations
20.
Vilsvik, Jan, et al.. (1968). The Effect of the Combined Antacid-Anticholinergic Treatment on the Intragastric pH in Peptic Ulcer Disease. Scandinavian Journal of Gastroenterology. 3(2). 170–176. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Der Sheng Sun Breakdown of academic impact, for papers by Akiko Fujii Breakdown of academic impact, for papers by Hisashi Mitsufuji Breakdown of academic impact, for papers by Sumio Matsumoto Breakdown of academic impact, for papers by Minehiko Inomata Breakdown of academic impact, for papers by Lawrence M. Knab Breakdown of academic impact, for papers by Toshiro Miwa Breakdown of academic impact, for papers by Marianne Corbel Breakdown of academic impact, for papers by Grant N. Stemmerman Breakdown of academic impact, for papers by Dong‐Hao Wu
Rankless by CCL
2026